Description of the Optune Lua® system

Discuss Optune Lua with your next patient

Optune Lua overview

- For the first-line **treatment of unresectable, locally advanced or metastatic, MALIGNANT PLEURAL MESOTHELIOMA (MPM)**, the FDA has approved Optune Lua together with pemetrexed + cisplatin or carboplatin[1,2]
- When using Optune Lua, **loco-regional delivery of Tumor Treating Fields (TTFields) via transducer arrays** provides antimitotic activity directly at the site of the malignancy[1]

How Optune Lua is used

- Transducer arrays are applied to the torso and need to be replaced at least twice per week (every 4 days at most) to help minimize the risk of skin irritation[3]
- Portable for use during normal daily activities[3]
  - Patients should avoid activities that may result in Optune Lua or the transducer arrays becoming wet, as this may cause damage[3]
- It is recommended to use TTFields continuously, averaging at least 18 hours a day[1,4]
- Patients should refer to the Skin Care Guidelines for specific information regarding taking care of their skin and array placement instructions

Introducing the second-generation Optune Lua system[3]

Second-generation Optune Lua system

Optune Lua is a wearable, portable treatment for MPM and has been redesigned for carrying comfort and usability. Note that the Optune Lua system is[1,3]:

More compact

- Smaller-profile carrying case with easy-grip texture

More convenient

- Weighs half as much and now has 5 different ways to carry the device, including a backpack and shoulder strap

Equipped with smart technology

- Battery indicator alerts patients to change battery, and light sensor auto-dims for night use

Note: Transducer arrays are customized based on gender, body type, and tumor location.

How Optune Lua works

Optune Lua is a noninvasive, antimitotic cancer treatment for MPM that delivers TTFields. TTFields are low-intensity (1-3 V/cm) alternating electric fields tuned to a specific frequency (150 kHz) to disrupt cancer cell division in solid tumors.[1]

TTFields disrupt cell division through physical interaction with key molecules during multiple phases of mitosis.[1,5]

Visit OptuneLua.com/hcp for more information

Caution: Federal law restricts this device to sale by or on the order of a physician. Humanitarian Device. Authorized by Federal Law for use in the treatment of adult patients with unresectable, locally advanced or metastatic, malignant pleural mesothelioma concurrently with pemetrexed and platinum-based chemotherapy. The effectiveness of this device for this use has not been demonstrated.

Please see the complete Important Safety Information for Optune Lua on the back and the Optune Lua Instructions For Use (IFU) for complete information regarding the device's indications, contraindications, warnings, and precautions at OptuneLua.com/hcp.

OPTUNE LUA®

Indications For Use

Optune Lua® is indicated for the treatment of adult patients with unresectable, locally advanced or metastatic, malignant pleural mesothelioma (MPM) to be used concurrently with pemetrexed and platinum-based chemotherapy.

Important Safety Information

Contraindications

Do not use Optune Lua in patients with implantable electronic medical devices such as pacemakers or implantable automatic defibrillators, etc. Use of Optune Lua together with implanted electronic devices has not been tested and may lead to malfunctioning of the implanted device.

Do not use Optune Lua in patients known to be sensitive to conductive hydrogels. Skin contact with the gel used with Optune Lua may commonly cause increased redness and itching, and may rarely lead to severe allergic reactions such as shock and respiratory failure.

Warnings and Precautions

Optune Lua can only be prescribed by a healthcare provider that has completed the required certification training provided by Novocure®.

The most common (≥10%) adverse events involving Optune Lua in combination with chemotherapy were anemia, constipation, nausea, asthenia, chest pain, fatigue, medical device site reaction, pruritus, and cough.

Other potential adverse effects associated with the use of Optune Lua include: treatment related skin toxicity, allergic reaction to the plaster or to the gel, electrode overheating leading to pain and/or local skin burns, infections at sites of electrode contact with the skin, local warmth and tingling sensation beneath the electrodes, muscle twitching, medical device site reaction and skin breakdown/skin ulcer.

If the patient has an underlying serious skin condition on the chest, evaluate whether this may prevent or temporarily interfere with Optune Lua treatment.

Do not prescribe Optune Lua for patients that are pregnant, you think might be pregnant or are trying to get pregnant, as the safety and effectiveness of Optune Lua in these populations have not been established.

Please see the Optune Lua Instructions For Use (IFU) included in the Information Kit for complete information regarding the device's indications, contraindications, warnings, and precautions.

References: 1. Optune Lua. Instructions For Use for Unresectable Malignant Pleural Mesothelioma. Novocure; 2021. **2.** FDA Approves the NovoTTF-100L™ System in Combination with Chemotherapy for the Treatment of Malignant Pleural Mesothelioma [press release]. St. Helier, Jersey: Business Wire; May 23, 2019. **3.** Optune Lua. Patient Information and Operation Manual for Unresectable Malignant Pleural Mesothelioma. Novocure; 2021. **4.** Ceresoli GL, Aerts JG, Dziadziuszko R, et al. Tumour Treating Fields in combination with pemetrexed and cisplatin or carboplatin as first-line treatment for unresectable malignant pleural mesothelioma (STELLAR): a multicentre, single-arm phase 2 trial. *Lancet Oncol*. 2019;20(12):1702-1709. **5.** Kirson ED, Gurvich Z, Schneiderman R, et al. Disruption of cancer cell replication by alternating electric fields. *Cancer Res*. 2004;64(9):3288-3295.

novocure®

OPTUNE LUA®